Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) Research & Development: 2022-2025

Historic Research & Development for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $330,589.

  • bioAffinity Technologies' Research & Development rose 20.43% to $330,589 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 6.88%. This contributed to the annual value of $1.5 million for FY2024, which is 0.46% down from last year.
  • Per bioAffinity Technologies' latest filing, its Research & Development stood at $330,589 for Q3 2025, which was up 6.17% from $311,372 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Research & Development registered a high of $450,612 during Q4 2022, and its lowest value of $248,419 during Q2 2022.
  • Its 3-year average for Research & Development is $358,046, with a median of $367,386 in 2025.
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 34.90% in 2023, then dropped by 22.63% in 2025.
  • bioAffinity Technologies' Research & Development (Quarterly) stood at $450,612 in 2022, then declined by 3.95% to $432,818 in 2023, then dropped by 9.74% to $390,658 in 2024, then increased by 20.43% to $330,589 in 2025.
  • Its Research & Development was $330,589 in Q3 2025, compared to $311,372 in Q2 2025 and $367,386 in Q1 2025.